TransMedics Group, Inc.
TMDX- Exchange
- Nasdaq
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001756262
In the last 90 days, TransMedics Group, Inc. insiders filed 1 open-market purchase and 0 sales; 375 institutions reported holding it in 13F filings for Q2 2026, worth $2.31B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by TransMedics Group, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $109.1K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$109.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for TransMedics Group, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Weill David | Director | 16,392 | Sep 14, 2026 | 4 |
| Tobin James R | Director | 0Indirect | Aug 17, 2026 | 2 |
| Corcoran Nicholas | See remarks | 41,558 | Jul 14, 2026 | 2 |
| Hernandez Gerardo | Chief Financial Officer | 31,935 | Jul 14, 2026 | 3 |
| Hassanein Waleed H | President & CEO | 171,093 | Jul 14, 2026 | 2 |
| Gunderson Thomas James | Director | 16,642 | Jun 17, 2026 | 2 |
| Raines Merilee | Director | 6,981 | May 22, 2026 | 1 |
| Kania Edwin M Jr | Director | 263,732 | May 22, 2026 | 1 |
| Lovell Stephanie | Director | 5,788 | May 22, 2026 | 2 |
| Basile Edward M | Director | 5,788 | May 22, 2026 | 2 |
| Forsyth Matthew S. | See Remarks | 15,409 | May 21, 2026 | 1 |
| Ranganath Anil P. | See remarks | 13,091 | Mar 4, 2026 | 2 |
| Cecere Giovanni | Chief Commercial Officer | 19,057 | Feb 20, 2026 | 1 |
| Khayal Tamer I | Chief Commercial Officer | 36,042 | Mar 5, 2025 | 0 |
| Gordon Stephen | Chief Financial Officer | 21,299 | Jun 5, 2024 | 0 |
| Provost Miriam | VP, Global Regulatory Affairs | 23,348 | Dec 15, 2023 | 0 |
| Damme Laura | VP, Clinical Affairs | 5,685 | Feb 22, 2023 | 0 |
| Carey John F | VP of Operations | 14,120 | Feb 3, 2023 | 0 |
| Sullivan John F | VP of Quality & Engineering | 14,273 | Sep 1, 2021 | 0 |
| Godhani Rakesh P. | Chief Digital Officer | – | Aug 6, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2022 (view filing)6:17 PM ET | Jul 5 | 1 day | Khayal Tamer IChief Commercial Officer | SSale | −13.5K | $35.06 | −$473.5K | −22.7%46.1K after | |
| Jul 6, 2022 (view filing) | Jul 5 | 1 day | Gordon StephenChief Financial Officer | SSale | −10.0K | $35.00 | −$350.0K | −63.6%5.71K after | |
| Jul 6, 2022 (view filing) | Jul 5 | 1 day | Tobin James RDirector | SSale | −48.5K | $35.00 | −$1.70M | −13.8%302.1K after | |
| Jun 29, 2022 (view filing)6:05 PM ET | Jun 28 | 1 day | Carey John FVP of Operations | SSale | −2.72K | $32.87 | −$89.5K | −87.8%379 after | |
| Jun 27, 2022 (view filing)7:59 PM ET | Jun 24 | 3 days | Carey John FVP of Operations | SSale | −2.96K | $32.57 | −$96.3K | −88.6%379 after | |
| Jun 27, 2022 (view filing)7:59 PM ET | Jun 27 | Same day | Carey John FVP of Operations | SSale | −3.32K | $32.59 | −$108.2K | −89.8%379 after | |
| Jun 3, 2022 (view filing)5:00 PM ET | Jun 1 | 2 days | Carey John FVP of Operations | SSale | −1.50K | $28.19 | −$42.3K | −79.8%379 after | 2 lots |
| May 6, 2022 (view filing)4:05 PM ET | May 4 | 2 days | Carey John FVP of Operations | SSale | −1.50K | $25.31 | −$38.0K | −79.8%379 after | |
| May 6, 2022 (view filing) | May 4 | 2 days | Tobin James RDirector | SSale | −48.5K | $29.94 | −$1.45M | −12.2%350.6K after | |
| Apr 4, 2022 (view filing)6:30 PM ET | Apr 1 | 3 days | Carey John FVP of Operations | SSale | −1.50K | $26.85 | −$40.3K | −79.8%379 after | |
| Mar 30, 2022 (view filing)7:19 PM ET | Mar 28 | 2 days | Carey John FVP of Operations | SSale | −4.50K | $25.01 | −$112.5K | −92.2%379 after | |
| Nov 30, 2021 (view filing) | Nov 29 | 1 day | Kania Edwin M JrDirector | PPurchase | +100.0K | $22.56 | +$2.26M | +49.3%302.9K after | 2 lots |
| Nov 2, 2021 (view filing) | Nov 1 | 1 day | Carey John FVP of Operations | SSale | −1.68K | $28.16 | −$47.3K | −100.0%0 after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Carey John FVP of Operations | SSale | −1.68K | $32.33 | −$54.3K | −100.0%0 after | 2 lots |
| Sep 17, 2021 (view filing) | Sep 15 | 2 days | Provost MiriamVP of US Regulatory & FDA Rel. | SSale | −3.88K | $31.34 | −$121.5K | −31.2%8.55K after | |
| Sep 9, 2021 (view filing)6:25 PM ET | Sep 7 | 2 days | Khayal Tamer IChief Commercial Officer | SSale | −3.94K | $35.08 | −$138.3K | −7.9%46.1K after | |
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Gordon StephenChief Financial Officer | SSale | −10.0K | $35.00 | −$350.0K | −63.6%5.71K after | |
| Sep 3, 2021 (view filing) | Sep 1 | 2 days | Carey John FVP of Operations | SSale | −1.68K | $31.98 | −$53.7K | −100.0%0 after | 2 lots |
| Aug 4, 2021 (view filing) | Aug 2 | 2 days | Carey John FVP of Operations | SSale | −1.68K | $28.33 | −$47.6K | −100.0%0 after | |
| Jul 19, 2021 (view filing)6:35 PM ET | Jul 15 | 4 days | Khayal Tamer IChief Commercial Officer | SSale | −5.15K | $35.10 | −$180.8K | −10.1%46.1K after | |
| Jul 16, 2021 (view filing) | Jul 15 | 1 day | Gordon StephenChief Financial Officer | SSale | −10.0K | $35.00 | −$350.0K | −63.6%5.71K after | |
| Jul 6, 2021 (view filing) | Jul 1 | 5 days | Carey John FVP of Operations | SSale | −1.68K | $33.65 | −$56.5K | −100.0%0 after | 2 lots |